Author

Junji Uchida

Observed names: J. Uchida, Uchida Junji

Institution: Toneyama National Hospital

Observed institutions: Toneyama National Hospital, National Hospital Organization

ORCID: 0000-0003-3629-6686

Observed ORCID: 0000-0003-3629-6686

OpenAlex ID: A5019946791

Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small cell lung cancer in a real-world setting (OSI-FACT-EP)

2023 · Yoshihiko Sakata, Go Saito, et al. · Lung Cancer · 16

Systemic Inflammation Modifies the Efficacy of Bevacizumab Added to Atezolizumab Plus Chemotherapy for Advanced Non‐Squamous Non‐Small Cell Lung Cancer: A Multicenter Retrospective Study

2026 · Keijiro Yamauchi, Kinnosuke Matsumoto, et al. · Thoracic Cancer · 1

Comparison of long-term survival between nivolumab plus ipilimumab with chemotherapy and pembrolizumab with chemotherapy in advanced non-small cell lung cancer: A multicenter retrospective cohort study

2026 · Yuhei Kinehara, Kinnosuke Matsumoto, et al. · Lung Cancer · 1

Corrigendum to “Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT-EP)” [Lung Cancer 186 (2023) 107426]

2023 · Yoshihiko Sakata, Go Saito, et al. · Lung Cancer · 1

Comparison of Long-Term Survival Between Nivolumab Plus Ipilimumab and Nivolumab Plus Ipilimumab With Chemotherapy in Advanced NSCLC: A Multicenter Retrospective Cohort Study

2026 · Kiyohide Komuta, Kinnosuke Matsumoto, et al. · JTO Clinical and Research Reports

Repotrectinib was effective for carcinomatous meningitis occurring during the treatment of early-generation ROS1 TKIs for ROS1 fusion-positive NSCLC: A case report

2026 · Yasuhiro Mihashi, Kenta Sugisawa, et al. · International Journal of Lung Cancer

EP.17.25 The Transition of Treatment Choice for First-Line Treatment for Advanced or Recurrent NSCLC and the Patients’ Characteristics

2025 · Y. Akazawa, A. Kubota, et al. · Journal of Thoracic Oncology

EP.13B.12 Chemotherapy Sensitivity for Recurrent Small-Cell Lung Cancer Based on Chemotherapy-Free Interval and Treatment Regimens

2024 · Y. Akazawa, A. Kubota, et al. · Journal of Thoracic Oncology

EP08.02-168 Efficacy, Safety and Treatment Courses for Patients with ALK Oncogene Positive NSCLC; Retrospective Data in Single Institute

2022 · Y. Akazawa, A. Yoshikawa, et al. · Journal of Thoracic Oncology

Works count: 9

Citation count: 19

H-index: 1

I10-index: 1